Anti-endothelial and anti-neuronal effects from auto-antibodies in subsets of adult diabetes having a cluster of microvascular complications

Diabetes Research and Clinical Practice

Volumn 93, Issue 1, 2011, Pages 95-105

  Zimering, Mark B ^a,b   Alder, Janet ^b   Pan, Zui ^b   Donnelly, Robert J ^c  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^c RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

Author keywords

Autoantibodies; Diabetes mellitus; Diabetic neuropathy; Endothelial cells; Neurite outgrowth

Indexed keywords

4 (1 AMINOETHYL) N (4 PYRIDYL)CYCLOHEXANECARBOXAMIDE; ALBUMIN; AUTOANTIBODY; BASIC FIBROBLAST GROWTH FACTOR; CALCIUM; CREATININE; GABAPENTIN; PROTEIN A; PROTEOHEPARAN SULFATE; RHO KINASE;

ADULT; AGED; ANIMAL CELL; ANTIBODY BLOOD LEVEL; ANTIBODY RESPONSE; ANTIGEN BINDING; ARTICLE; CALCIUM CELL LEVEL; CELL STRAIN; CELL SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; CREATININE URINE LEVEL; DIABETIC MACULAR EDEMA; DIABETIC NEPHROPATHY; DIABETIC NEUROPATHY; DISEASE ASSOCIATION; DISEASE DURATION; DISEASE SEVERITY; DRUG MECHANISM; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; MALE; NERVE CELL INHIBITION; NEUROPATHIC PAIN; NONHUMAN; PHEOCHROMOCYTOMA CELL; PROTEIN URINE LEVEL; RAT; RISK FACTOR;

ADULT; AGED; AGED, 80 AND OVER; ALBUMINS; AMIDES; ANIMALS; AUTOANTIBODIES; CATTLE; CELL PROLIFERATION; CELLS, CULTURED; CHROMATOGRAPHY, AFFINITY; DIABETIC NEUROPATHIES; ELECTROPHYSIOLOGY; ENDOTHELIAL CELLS; FIBROBLAST GROWTH FACTOR 2; HEPARAN SULFATE PROTEOGLYCANS; HUMANS; MALE; MIDDLE AGED; NEURITES; PC12 CELLS; PROSTATIC NEOPLASMS; PYRIDINES; RATS; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION;

EID: 79960503077     PISSN: 01688227     EISSN: 18728227     Source Type: Journal    
DOI: 10.1016/j.diabres.2011.03.029     Document Type: Article

References (38)

1. Malik R.A., Newrick P.G., Sharma A.K., Jennings A., Ah-See A.K., Mayhew T.M., et al. Microangiopathy in human diabetic neuropathy: relationship between capillary abnormalities and the severity of neuropathy. Diabetologia 1989, 32:92-102.
2. Young R.J., Macintyre C.C., Martyn C.N., Prescott R.J., Ewing D.J., Smith A.F., et al. Progression of subclinical polyneuropathy in young patients with type 1 (insulin-dependent) diabetes: associations with glycaemic control and microangiopathy (microvascular complications). Diabetologia 1986, 29(3):156-161.
3. Dyck P.J., Davies J.L., Wilson D.M., Service F.J., Melton L.J., O'Brien P.C. Risk factors for severity of diabetic polyneuropathy: intensive longitudinal assessment of the Rochester Diabetic Neuropathy Study cohort. Diabetes Care 1999, 22(9):1479-1486.
4. Deckert T., Feldt-Rasmussen B., Borch-Johnsen K., Jensen T., Kofoed-Enevoldsen A. Albuminuria reflects widespread vascular damage: the Steno hypothesis. Diabetologia 1989, 32:219-226.
5. Sheikh K.A., Zhang G., Gong Y., Schnaar R.L., Griffin J.W. An anti-ganglioside antibody-secreting hybridoma induces neuropathy in mice. Ann Neurol 2004, 56(2):228-239.
6. van Nieuw Amerongen G.P., Beckers C.M., Achekar I.D., Zeeman S., Musters R.J., van Hinsbergh V.W. Involvement of Rho kinase in endothelial barrier maintenance. Arterioscler Thromb Vasc Biol 2007, 27:2332-2339.
7. Zimering M.B., Anderson R.J., Moritz T.E., Ge L. Low plasma basic fibroblast growth factor is associated with laser photocoagulation treatment in adult type 2 diabetes mellitus from the Veterans Affairs Diabetes Trial. Metabolism 2009, 58:393-400. Investigators for the VADT.
8. Zimering M.B., Pan Z. Autoantibodies in type 2 diabetes induce stress fiber formation and apoptosis in endothelial cells. J Clin Endo Metab 2009, 94(6):2171-2177.
9. Govek E.E., Newey S.E., Van Aelst L. The role of the Rho GTPases in neuronal. Development Genes Dev 2005, 19(1):1-49.
10. Zimering M.B., Thakker-Varia S. Increased fibroblast growth factor-like autoantibodies in serum from a subset of patients with cancer-associated hypercalcemia. Life Sci 2002, 71(25):2939-2959.
11. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 1983, 65(12):55-63.
12. Kaji T., Yamada A., Miyajima S., Yamamoto C., Fujiwara Y., Wight T.N., et al. Cell density-dependent regulation of proteoglycan synthesis by transforming growth factor beta1 in cultured bovine aortic endothelial cells. J Biol Chem 2000, 275(2):1463-1470.
13. Zimering M.B., Brandi M.L., deGrange D.A., Marx S.J., Streeten E., Katsumata N., et al. Circulating fibroblast growth factor-like substance in familial multiple endocrine neoplasia type 1. J Clin Endocrinol Metab 1990, 70(1):149-154.
14. Zimering M.B., Alder J., Thakker-Varia S. Neurotrophic effects of fibroblast growth factor-like autoantibodies in serum from three patients with breast cancer. Brain Res 2009, 1251:276-286.
15. Fuxe K., Chadi G., Tinner B., Agnati L.F., Pettersson R., David G. On the regional distribution of heparan sulfate proteoglycan immunoreactivity in the rat brain. Brain Res 1994, 636(1):131-138.
16. Poduslo J.F., Curran G.L., Dyck P.J. Increase in albumin, IgG, and IgM blood-nerve barrier indices in human diabetic neuropathy. Proc Natl Acad Sci USA 1988, 85:4879-4883.
17. Kanda T., Iwaski T., Yamawaki M., Tai T., Mizusawa H. Anti-GM1 antibody facilitates leakage in an in vitro blood-nerve barrier model. Neurology 2000, 55(4):587-597.
18. Schubert D., Ling N., Baird A. Multiple influences of a heparin-binding growth factor on neuronal development. J Cell Biol 1987, 104:635-643.
19. Vlodavsky I., Friedmann Y., Elkin M., Aingorn H., Atzmon R., Ishai-Michaeli R., et al. Mammalian heparanase: gene cloning, expression and function in tumor progression and metastasis. Nat Med 1999, 5:793-802.
20. Kosir M.A., Quinn C.C., Zukowski K.L., Grignon D.J., Ledbetter S. Human prostate carcinoma cells produce extracellular heparanase. J Surg Res 1997, 67(1):98-105.
21. Nicolson G.L., Custead S.E., Dulski K.M., Milas L. Effects of gamma irradiation on cultured rat and mouse microvessel endothelial cells: metastatic tumor cell adhesion, subendothelial matrix degradation, and secretion of tumor cell growth factors. Clin Exp Metastasis 1991, 9(5):457-468.
22. van den Hoven M.J., Rops A.L., Bakker M.A., Aten J., Rutjes N., et al. Increased expression of heparanase in overt diabetic nephropathy. Kidney Int 2006, 70:2100-2108.
23. Larsson S.C., Orsini N., Brismar K., Wolk A. Diabetes mellitus and risk of bladder cancer: a meta-analysis. Diabetologia 2006, 49(12):2819-2823.
24. Vom Dorp F., Sanders H., Boergermann C., Lümmen G., Rübben H., Jakobs K.H., et al. Inhibition of rho-kinase abrogates migration of human transitional cell carcinoma cells: results of an in vitro study. Urol Int 2011, 86(2):220-227.
25. Hayashi K., Hayashi M., Jalkanen M., Firestone J.H., Trelstad R.L., Bernfield M. Immunocytochemistry of cell surface heparan sulfate proteoglycan in mouse tissues. A light and electron microscopic study. J Histochem Cytochem 1987, 35(10):1079-1088.
26. Poulsen K., Fraser K.J., Haber E. An active derivative of rabbit antibody light chain composed of the constant and the variable domains held together only by a native disulfide bond. Proc Natl Acad Sci USA 1972, 69(9):2495-2499.
27. Saoncella S., Echtermeyer F., Denhez F., Nowlen J.K., Mosher D.F., Robinson S.D., et al. Syndecan-4 signals cooperatively with integrins in a Rho-dependent manner in the assembly of focal adhesions and actin stress fibers. Proc Natl Acad Sci USA 1999, 96:2805-2810.
28. Kranenburg O., Poland M., van Horck F.P., Drechsel D., Hall A., Moolenaar W.H. Activation of RhoA by lysophosphatidic acid and Galpha12/13 subunits in neuronal cells: induction of neurite retraction. Mol Biol Cell 1999, 10(6):1851-1857.
29. 2+ release by a rho-kinase inhibitor for the treatment of ischemic damage in primary cultured rat. hippocampal neurons. Eur J Pharmacol 2009, 84:238-244.
30. 2+ entry by Rho-kinase in tracheal smooth muscle. Am J Respir Cell Mol Biol 2002, 26(4):491-498.
31. Srinivasan S., Stevens M.J., Sheng H., Hall K.E., Wiley J.W. Serum from patients with type 2 diabetes with neuropathy induces complement-independent, calcium-dependent apoptosis in cultured neuronal cells. J Clin Invest 1998, 102:1454-1462.
32. Stevens F.J., Kisilevsky R. Immunoglobulin light chains, glycosaminoglycans, and amyloid. Cell Mol Life Sci 2000, 57(3):441-449.
33. Lu S.G., Zhang X., Gold M.S. Intracellular calcium regulation among subpopulations of rat dorsal root ganglion neurons. J Physiol (Lond) 2006, 577:169-190.
34. Briani C., Ruggero S., Alaedini A., Nardelli E., Ferrari S., Wirquin I., et al. Anti-heparan sulfate antibodies in neurological disease. Muscle Nerve 2002, 5:713-715.
35. Pestronk A., Choksi R., Logigian E., Al-Lozi M.T. Sensory neuropathy with monoclonal IgM binding to a trisulfated heparin disaccharide. Muscle Nerve 2003, 27(2):188-195.
36. Pittenger G.I., Malik R.A., Burcus N., Boulton A.J., Vinik A.I. Specific fiber deficits in sensorimotor diabetic polyneuropathy correspond to cytotoxity against neuroblastoma cells of sera from patients with diabetes. Diabetes Care 1999, 22:1839-1844.
37. Tai A.W., Newkirk M.M. An autoantibody targeting glycated IgG is associated with elevated serum immune complexes in rheumatoid arthritis (RA). Clin Exp Immunol 2000, 120(1):188-193.
38. Tarkowski A., Westberg G. Rheumatoid factor isotypes and renal disease in systemic lupus erythematosus. Scand J Rheumatol 1987, 16(5):309-312.